Research on treating disease with medication. Covers psychedelics, combination cancer therapy, opioid treatment in pregnancy, and personalized guidelines.
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
A UBCO study found that patients face barriers when discussing psychedelics with physicians due to stigma and perceived lack of knowledge. The study analyzed data from 800 adults who use psychedelics, revealing that nearly 60% felt less satisfied with communication about psychedelics compared to previous conversations.
A clinical trial found that sulthiame, a drug used for epilepsy, reduces pauses in breathing and improves oxygen levels in patients with obstructive sleep apnea. The treatment also alleviates daytime fatigue, suggesting it could be an effective alternative to existing mechanical treatments.
The FDA Letter of Support recognizes the potential of αSyn-SAA to accelerate clinical trial design in Parkinson's and related disorders. This biomarker can objectively detect early biology related to these diseases, enabling research toward tailored therapies and potentially delaying or preventing disease onset.
A four-year grant will help researchers find new clues to the interplay between Down syndrome and myeloid leukemia, focusing on enhancing antileukemic activity of chemotherapy drug cytarabine. The goal is to identify a novel treatment strategy to improve patient outcomes and prevent relapses in ML-DS patients.
Researchers at Johns Hopkins Medicine found that age-related changes in male fibroblasts contribute to more aggressive and treatment-resistant melanomas. The study discovered that male fibroblasts accumulate reactive oxygen species and produce higher levels of BMP2, leading to increased DNA damage and resistance to targeted therapies.
A new framework from a global team of scientists aims to overcome translational hurdles in nanomedicine development. The DELIVER guidelines provide early-stage recommendations for maximizing clinical translation and enabling the successful development of new nanomedicine treatments.
A literature review examines key cell-cell interactions driving pulmonary fibrosis, revealing complex interplay between diverse lung cell types and intricate processes. The study highlights potential ligands involved in PF, including tumor necrosis factor, interleukin 1β, and ADAM17, and suggests targeting CCIs for novel therapies.
Researchers developed a gene therapy that restored useful vision to most patients with Leber congenital amaurosis type I, a rare inherited blindness. The treatment showed a 10,000-fold improvement in light sensitivity and improved navigation abilities in patients who received the highest dose.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
A low-dose triple-pill protocol demonstrated improved blood pressure lowering and control, with good tolerability, compared to standard-care protocols for Black African adults with uncontrolled hypertension. The study results have significant implications for hypertension treatment in Nigeria.
Researchers have developed a new method to increase speed and success rates in drug discovery by combining data from the Library of Integrated Network-based Cellular Signatures with targeted docking simulations. This approach can accelerate the drug research process, identifying potentially effective compounds more efficiently.
The Northwestern University Clinical and Translational Sciences Institute has received $55 million in NIH funding to accelerate the development, evaluation, and implementation of improved healthcare interventions. The grant will support the development of effective health interventions for more patients more quickly, with a focus on ad...
Researchers at the University of Hawaii have developed a new gene editing technology that can efficiently deliver healthy genes to the body. This method addresses limitations of current methods and has shown success rates of up to 96%, potentially leading to faster and more affordable treatments for various genetic diseases.
Researchers have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease. The treatment approach may represent a potential long-term universal treatment for MSUD.
A multi-university research team led by University of Virginia engineering professor Gustavo K. Rohde has developed a system that can accurately spot genetic markers of autism in brain images. The system uses generative computer modeling technique called transport-based morphometry, which reveals brain structure patterns that predict v...
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
Recent years have seen therapeutic advances in kidney cancer due to deeper understanding of the disease's biology, with improved treatments and early detection contributing to decreased deaths. Cigarette smoking and being overweight remain major risk factors for kidney cancer.
A five-year study led by Tulane University is investigating a new medication to treat trichomoniasis. The research compares secnidazole with metronidazole, finding that one-dose treatment could offer better options for the infection, which affects 156 million people annually.
TCT 2024 features groundbreaking research on minimally invasive techniques, pharmaceuticals, technologies, and devices to treat or prevent cardiovascular disease. The event showcases the latest advancements in interventional cardiology and offers a platform for clinicians to learn about new interventions and strategies.
A new study published in Alzheimer's & Dementia found that cholinesterase inhibitors (ChEIs) may slow down cognitive decline in dementia with Lewy bodies over five years. ChEIs were also associated with a reduced risk of death in the first year after diagnosis.
Researchers at Åbo Akademi University have discovered a crucial protein, TLNRD1, that helps maintain blood vessel stability in the brain. The study highlights the potential for targeted molecular therapies to improve patient outcomes in CCM disease.
Researchers explore clinical diagnosis and treatment strategies tailored to rare genetic profiles in colorectal cancer. Advances in sequencing technologies have uncovered numerous rare genetic mutations tied to poor prognosis, emphasizing the need for personalized approaches.
Researchers developed tumor cell-coated carbon nanohorns to deliver paclitaxel to colon cancer, exhibiting high accumulation at tumors and strong chemotherapeutic effects. The treatment also demonstrated a robust photothermal effect and immune responses, effectively destroying tumors.
Researchers at the University of Virginia School of Engineering and Applied Science have designed a drug-carrying molecule that can slip past the lung's natural defenses. The nanocarrier, called PEG-BB, is shaped like a bottlebrush and mimics the properties of mucus, allowing it to move quickly through the airway.
Elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated significant reductions in vasomotor symptoms frequency and severity vs placebo in postmenopausal individuals with moderate to severe VMS. The treatment also improved sleep disturbances and menopause-related quality of life, with a favorable safety profile.
Researchers developed a treatment approach using lipid nanoparticles to deliver mRNA therapy for MSUD, extending survival and reducing serum leucine levels. The study also identified a novel AAV variant with desirable biodistribution properties for targeting peripheral organs.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.
A clinical study confirmed the safety of aceneuramic acid in treating distal myopathy with rimmed vacuoles (GNE myopathy), a rare disease causing progressive muscle weakness. The treatment, developed for an ultra-orphan drug, showed efficacy and was approved by Japan's Ministry of Health, Labour and Welfare.
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
A wearable sensor supported by machine learning models can continuously monitor and quantify FOG episodes, providing an accurate picture of a patient's condition. This technology has the potential to support the development of new treatments and improve the lives of people with Parkinson's disease.
The International Space Station National Laboratory is collaborating with NASA to fund up to $4 million in research addressing significant diseases like cancer, cardiovascular disease, and neurodegenerative disease. The joint solicitation aims to leverage microgravity to improve existing or develop new technologies for health problems ...
Texas A&M researchers are investigating the use of extracellular vesicles to deliver immune-suppressing proteins, potentially reducing the immune system's attack on insulin-producing beta-cells. The goal is to develop a novel treatment for type 1 diabetes, which currently has only lifelong insulin therapy as an approved option.
A team of researchers, led by Jason Shoemaker, are studying the effects of hormones on the immune system's response to the flu. Their goal is to develop targeted therapies based on a person's sex or hormone levels. The study aims to identify the molecules or pathways that affect the cells and begin to develop personalized treatments.
Researchers have identified new immune checkpoints, including T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3), which help tumors evade the immune system.
UMass Amherst researchers have identified the 'quality control' regulator for protein folding, a crucial process that ensures essential cellular functions. The discovery of this regulator, Sep15, could lead to new treatments targeting misfolded proteins associated with diseases like Alzheimer's and cystic fibrosis.
Pregnant women exposed to buprenorphine combined with naloxone had similar or more favorable outcomes compared to those exposed to buprenorphine alone. This suggests that both formulations are safe treatment options for opioid use disorder during pregnancy.
Researchers from Tokyo University of Science have developed an efficient method to synthesize eutyscoparol A and violaceoid C, two compounds with potential therapeutic properties. The new approach improves yields and simplifies synthesis steps, enabling further research into their pharmacological effects.
Researchers from POSTECH and KRICT created a 3D artificial lung using bioprinting technology, closely mimicking the human respiratory tract. This model allows for accurate testing of COVID-19 drugs and development of therapeutic treatments, potentially shortening the drug development process to under 5 years.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Researchers at Michigan State University characterized how fungi restructure their cell walls to thwart current antifungal medications. The study found that fungi enhance their survival odds by making specific changes to the structure and organization of the components in their cell walls, rendering existing drugs ineffective.
Researchers analyzed data from 63,700 patients in five clinical trials to understand the impact of clonal hematopoiesis of indeterminate potential (CHIP) on heart disease. They found that patients with CHIP had a 30% higher risk of initial heart attacks but not recurrent events.
Researchers question the effectiveness of new amyloid immunotherapy drugs in reducing Alzheimer's disease impact, citing limited eligibility and high costs. The drugs showed small effect sizes that may not outweigh the risk of adverse events.
A new editorial published in Aging suggests that starting targeted cancer therapies with high concentrations may slow down the selection for resistance. This approach could potentially be used as a preemptive measure to minimize the development of resistance.
A study found that increased expression of human carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) on immune cells is associated with treatment-resistant melanoma. CEACAM1 is now considered a potential therapeutic target for patients with resistant tumors.
A survey study estimates that 15.6 million US adults consume at least one potentially hepatotoxic botanical product within the past 30 days. Turmeric is the most commonly reported botanical, followed by green tea, ashwagandha, Garcinia cambogia, red yeast rice, and black cohosh products.
A new study found that subclinical hypothyroidism diagnosed before 21 weeks of pregnancy is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years after delivery. Women with high TSH values and elevated TPO antibodies were at increased risk.
Researchers at H. Lee Moffitt Cancer Center & Research Institute propose a unified framework for understanding antifragility in complex systems, including cancer. The study suggests that applying principles of antifragility could lead to dynamic and responsive cancer therapies.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.
A recent study published in Scientific Reports found that blocking connexin 43 (Cx43) channels with the compound INI-0602 improved MS symptoms in an animal model by regulating immune processes and reducing inflammation. The findings suggest a potential therapeutic strategy for chronic MS treatment.
Researchers found that a cancer drug can restore phagocytosis, a process crucial for brain health, in individuals with Rett syndrome by targeting microglia. The study highlights the potential therapeutic target of microglia in neurological conditions and may lead to new treatments.
A recent study found that 'gene misbehaviour' is a common phenomenon in the healthy human population, with over half of inactive genes showing misexpression. The researchers used advanced techniques to analyze blood samples from 4,568 healthy individuals and identified mechanisms behind these gene activity errors.
Researchers developed a triple-adeno-associated virus vector system to deliver full-length dystrophin protein into muscles, restoring muscle health and strength in mice models with Duchenne muscular dystrophy. The approach has shown promise for treating patients with the genetic disorder.
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.